Man Group PLC Axsome Therapeutics, Inc. Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$39.94 - $79.72 $4.65 Million - $9.29 Million	116,492 New	116,492 $8.99 Million
Q3 2021 Nov 15, 2021	SELL	$19.91 - $68.26 $159,160 - $545,670	-7,994 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$50.63 - $73.5 $1.72 Million - $2.49 Million	-33,907 Reduced 80.92%	7,994 $539,000
Q1 2021 May 17, 2021	BUY	$55.91 - $81.44 $77,994 - $113,608	1,395 Added 3.44%	41,901 $2.37 Million
Q4 2020 Feb 16, 2021	SELL	$66.31 - $86.52 $152,778 - $199,342	-2,304 Reduced 5.38%	40,506 $3.3 Million
Q3 2020 Nov 16, 2020	BUY	$68.34 - $85.84 $1.94 Million - $2.44 Million	28,383 Added 196.74%	42,810 $3.05 Million
Q2 2020 Aug 14, 2020	BUY	$49.87 - $98.69 $719,474 - $1.42 Million	14,427 New	14,427 $1.19 Million

325

37.7M

912K

855K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.74B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.